Looking Abroad

Germany's Biotech Blind Spot

Laboratory woman employee magnifier biotech research Source Corbis 46780602
German investors could be overlooking biotech opportunities, which are right under their nose.
  • Why it matters

    Why it matters

    German biotech firms are growing but technology and jobs may end up abroad if domestic investors continue to ignore them.

  • Facts


    • Curetis wants to list on a stock exchange this year, but may choose not to do so in Germany.
    • When Munich-based Medigene raised €46 million ($50.6 million) for research into cancer immunotherapy, only five percent of investors were from Germany.
    • Halle-based Probiodrug listed its stocks in 2014 in Amsterdam while Heidelberg-based Affimed listed on Nasdaq in New York.
  • Audio


  • Pdf

The fight against drug-resistant germs in hospitals is a major focus of the start-up biotech company Curetis. The firm, founded in 2007, has developed a diagnostic system to locate bacterial infections more quickly, identify them more precisely identified and, as a result, treat them more effectively.

This year Curetis faces another type of resistance: The wariness German investors feel for the biotech industry.

Curetis, based near Stuttgart, plans an initial public offering in the fourth quarter to bring in fresh capital in the mid-double digit millions range. The money is primarily earmarked for a planned expansion in the U.S. market and development of its own sales force in North America.

Want to keep reading?

Subscribe now or log in to read our coverage of Europe’s leading economy.